Company record · IMA · Biological Products, (No Diagnostic Substances)
ImageneBio, Inc.
ImageneBio, Inc.'s chief financial officer on the record is Yanina Grant-Huerta, effective July 20, 2026, per the filing record.
The record holds 1 verified CFO change for ImageneBio, Inc. from Form 8-K filings, filed July 23, 2026 and its 10-K filed March 10, 2026, where no CFO signature could be established.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Yanina Grant-Huerta |
| Title as printed | Chief Financial Officer, principal financial officer and principal accounting officer |
| Basis | Latest move: transition, 8-K filed July 23, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-07-23Transition
ImageneBio, Inc. CFO transition: Yanina Grant-Huerta to succeed Kristin Yarema, Ph.D.effective July 20, 2026 · 8-K filed July 23, 2026 · sec.gov, Item 5.02
2026-03-1010-K signature
CFO signature not established from the annual report
10-K filed March 10, 2026 · sec.gov
Company
| Ticker | IMA |
|---|---|
| SEC CIK | 0001835579 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | From the 10-K filed 2026-03-10: no conformed signature "/s/ Kristin Yarema, Ph.D." in the signature section. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
Precision BioSciences, Inc.DTIL
CFO: Naresh Tanna · effective August 1, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.